Innate Pharma (NASDAQ:IPHA) Upgraded by BTIG Research to Strong-Buy Rating

Innate Pharma (NASDAQ:IPHA) was upgraded by equities research analysts at BTIG Research to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Innate Pharma Price Performance

NASDAQ IPHA opened at $1.50 on Wednesday. Innate Pharma has a 52 week low of $1.40 and a 52 week high of $2.63. The stock has a fifty day moving average of $1.71 and a 200-day moving average of $1.86.

Institutional Investors Weigh In On Innate Pharma

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new position in shares of Innate Pharma during the fourth quarter worth $36,000. OLD Mission Capital LLC bought a new stake in shares of Innate Pharma in the 4th quarter valued at $50,000. Finally, Jane Street Group LLC bought a new stake in shares of Innate Pharma in the 4th quarter valued at $162,000. 0.16% of the stock is currently owned by institutional investors and hedge funds.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.